|
1
|
Heidenreich A, Bellmunt J, Bolla M, Joniau
S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel
T, et al: EAU guidelines on prostate cancer Part 1: Screening,
diagnosis, and treatment of clinically localised disease. Eur Urol.
59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mottet N, Bellmunt J, Bolla M, Joniau S,
Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F
and Heidenreich A: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 59:572–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilson KM, Giovannucci EL and Mucci LA:
Lifestyle and dietary factors in the prevention of lethal prostate
cancer. Asian J Androl. 14:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Platz EA, Clinton SK and Giovannucci E:
Association between plasma cholesterol and prostate cancer in the
PSA era. Int J Cancer. 123:1693–1698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Platz EA, Till C, Goodman PJ, Parnes HL,
Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr and
Kristal AR: Men with low serum cholesterol have a lower risk of
high-grade prostate cancer in the placebo arm of the prostate
cancer prevention trial. Cancer Epidemiol Biomarkers Prev.
18:2807–2813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mondul AM, Clipp SL, Helzlsouer KJ and
Platz EA: Association between plasma total cholesterol
concentration and incident prostate cancer in the CLUE II cohort.
Cancer Causes Control. 21:61–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Platz EA, Leitzmann MF, Visvanathan K,
Rimm EB, Stampfer MJ, Willett WC and Giovannucci E: Statin drugs
and risk of advanced prostate cancer. J Natl Cancer Inst.
98:1819–1825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allott EH, Howard LE, Cooperberg MR, Kane
CJ, Aronson WJ, Terris MK, Amling CL and Freedland SJ:
Postoperative statin use and risk of biochemical recurrence
following radical prostatectomy: Results from the Shared Equal
Access Regional Cancer Hospital (SEARCH) database. BJU Int.
114:661–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu O, Eberg M, Benayoun S, Aprikian A,
Batist G, Suissa S and Azoulay L: Use of statins and the risk of
death in patients with prostate cancer. J Clin Oncol. 32:5–11.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH and Wittekind CH: UICC. TNM
Classification of Malignant Tumours (6th). Wiley. (New York).
2002.
|
|
11
|
World Health Organization: Obesity:
Preventing and Managing the Global Epidemic. WHO Technical Report
Series no 894 (WHO, Geneva). 2000.
|
|
12
|
de Martino M, Leitner CV, Seemann C,
Hofbauer SL, Lucca I, Haitel A, Shariat SF and Klatte T:
Preoperative serum cholesterol is an independent prognostic factor
for patients with renal cell carcinoma (RCC). BJU Int. 115:397–404.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhuang L, Kim J, Adam RM, Solomon KR and
Freeman MR: Cholesterol targeting alters lipid raft composition and
cell survival in prostate cancer cells and xenografts. J Clin
Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eichholzer M, Stähelin HB, Gutzwiller F,
Lüdin E and Bernasconi F: Association of low plasma cholesterol
with mortality for cancer at various sites in men: 17-y follow-up
of the prospective Basel study. Am J Clin Nutr. 71:569–572.
2000.PubMed/NCBI
|
|
15
|
Batty GD, Kivimäki M, Clarke R, Smith
Davey G and Shipley MJ: Modifiable risk factors for prostate cancer
mortality in London: Forty years of follow-up in the Whitehall
study. Cancer Causes Control. 22:311–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solomon KR and Freeman MR: The complex
interplay between cholesterol and prostate malignancy. Urol Clin
North Am. 38:243–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muldoon MF, Marsland A, Flory JD, Rabin
BS, Whiteside TL and Manuck SB: Immune system differences in men
with hypo- or hypercholesterolemia. Clin Immunol Immunopathol.
84:145–149. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amling CL, Kane CJ, Riffenburgh RH, Ward
JF, Roberts JL, Lance RS, Friedrichs PA and Moul JW: Relationship
between obesity and race in predicting adverse pathologic variables
in patients undergoing radical prostatectomy. Urology. 58:723–728.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siddiqui SA, Inman BA, Sengupta S, Slezak
JM, Bergstralf EJ, Leibovich BC, Zincke H and Blute ML: Obesity and
survival after radical prostatectomy: A 10-year prospective cohort
study. Cancer. 107:521–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loeb S, Yu X, Nadler RB, Roehl KA, Han M,
Hawkins SA and Catalona WJ: Does body mass index affect
preoperative prostate specific antigen velocity or pathological
outcomes after radical prostatectomy? J Urol. 177:102–106;
discussion 106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Narita S, Mitsuzuka K, Yoneyama T,
Tsuchiya N, Koie T, Kakoi N, Kawamura S, Kaiho Y, Oyama C, Tochigi
T, et al: Impact of body mass index on clinicopathological outcome
and biochemical recurrence after radical prostatectomy. Prostate
Cancer Prostatic Dis. 16:271–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SE, Lee WK, Jeong MS, Abdullajanov M,
Kim DS, Park HZ, Jeong SJ, Yoon CY, Byun SS, Choe G, et al: Is body
mass index associated with pathological outcomes after radical
prostatectomy in Korean men? BJU Int. 107:1250–1255. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kitahara CM, de Berrington González A,
Freedman ND, Huxley R, Mok Y, Jee SH and Samet JM: Total
cholesterol and cancer risk in a large prospective study in Korea.
J Clin Oncol. 29:1592–1598. 2011. View Article : Google Scholar : PubMed/NCBI
|
